Trials / Completed
CompletedNCT01970488
Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Efficacy and Safety of ABP 501 Compared With Adalimumab in Subjects With Moderate to Severe Plaque Psoriasis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 350 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to compare the efficacy and safety of ABP 501 and adalimumab (HUMIRA®) in adults with plaque psoriasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Adalimumab | Administered by subcutaneous injection |
| BIOLOGICAL | ABP 501 | Administered by subcutaneous injection |
Timeline
- Start date
- 2013-10-18
- Primary completion
- 2014-08-14
- Completion
- 2015-03-18
- First posted
- 2013-10-28
- Last updated
- 2019-04-03
- Results posted
- 2016-12-13
Locations
3 sites across 3 countries: Australia, Canada, Hungary
Source: ClinicalTrials.gov record NCT01970488. Inclusion in this directory is not an endorsement.